MedPath

Beclomethasone Dipropionate

Generic Name
Beclomethasone Dipropionate
Brand Names
Alanase, Beconase, Propaderm, Qnasl, Qvar, Rivanase AQ
Drug Type
Small Molecule
Chemical Formula
C28H37ClO7
CAS Number
5534-09-8
Unique Ingredient Identifier
5B307S63B2
Background

Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to dexamethasone. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Beclomethasone dipropionate itself posesses weak glucocorticoid receptor binding affinity and is rapidly converted into 17-BMP upon administration. Formulations for oral inhalation, intranasal, and topical use are available for beclomethasone dipropionate. Beclomethasone dipropionate became first available in a pressurized metered-dose inhaler in 1972 and later in a dry powder inhaler and an aqueous nasal spray. Due to its anti-inflammatory, antipruritic, and anti-allergy properties, beclomethasone dipropionate is used in various inflammatory conditions, such as asthma, allergic rhinitis, and dermatoses to reduce symptoms. When inhaled, it is proposed that beclomethasone dipropionate remains active locally in the lung without causing significant side effects associated with systemic corticosteroids. Compared to earlier corticosteroids such as dexamethasone and prednisolone, beclomethasone dipropionate is reported to be less irritating to the nasal mucosa with a longer duration of action when administered intranasally.

Indication

糖皮质激素类药。主要用于持续性哮喘的长期治疗。按照支气管哮喘严重程度分级标准,在轻度持续(2级以上)即可使用吸入糖皮质激素治疗;外用适用于对糖皮质激素外用有效的各种非感染性炎症性皮肤病,如亚急性和慢性湿疹、脂溢性皮炎、接触性皮炎、特应性皮炎、局限性神经性皮炎、寻常型银屑病、盘状红斑狼疮、扁平苔癣等。亦可用于常年性变应性鼻炎和季节性变应性鼻炎及血管收缩性鼻炎;亦用于鼻息肉切除术后,预防息肉的再生。

Associated Conditions
Asthma, Bacterial Sinusitis, Chronic Sinusitis, Dermatosis, Fungal skin infection, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Recurrent nasal polyps

Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough.

Not Applicable
Not yet recruiting
Conditions
Cough
Interventions
First Posted Date
2023-06-05
Last Posted Date
2023-07-11
Lead Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Target Recruit Count
520
Registration Number
NCT05888350
Locations
🇨🇳

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Phase 1
Completed
Conditions
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
First Posted Date
2023-04-26
Last Posted Date
2023-10-31
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
95
Registration Number
NCT05830071
Locations
🇺🇸

PAREXEL Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States

A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Beclomethasone Dipropionate/Formoterol Fumarate
First Posted Date
2022-03-23
Last Posted Date
2025-01-24
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
1377
Registration Number
NCT05292586
Locations
🇺🇸

Chiesi Clinical Trial Site 840833, Houston, Texas, United States

🇺🇸

Chiesi Clinical Trial Site 840819, Miami, Florida, United States

🇺🇸

Chiesi Clinical Trial Site 840887, Miami, Florida, United States

and more 88 locations

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

Phase 4
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Other: Matched placebo
First Posted Date
2021-10-27
Last Posted Date
2023-03-24
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
106
Registration Number
NCT05097014
Locations
🇩🇪

PAREXEL International GmbH Early Phase Clinical Unit Berlin, Berlin-Spandau, Berlin Spandauer Damm, Germany

Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers

Phase 1
Completed
Conditions
Healthy Adult Male Volunteers
Interventions
First Posted Date
2021-05-05
Last Posted Date
2022-05-04
Lead Sponsor
SOFAR S.p.A.
Target Recruit Count
28
Registration Number
NCT04873063
Locations
🇮🇹

Centro Ricerche Cliniche AOU Integrata di Verona - Policlinico Universitario G.B. Rossi, Verona, Italy

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

Phase 3
Active, not recruiting
Conditions
COPD
COPD Exacerbation
Interventions
First Posted Date
2020-03-25
Last Posted Date
2025-04-02
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
3433
Registration Number
NCT04320342
Locations
🇧🇬

Chiesi Clinical Trial Site 100113, Ruse, Bulgaria

🇺🇸

Chiesi Clinical Trial Site 840206, Montgomery, Alabama, United States

🇺🇸

Chiesi Clinical Trial Site 840144, Westminster, California, United States

and more 433 locations

Comparison Efficacy in Patients With Asthma Using Foster MDI and Relvar Medications

Phase 4
Conditions
Asthma
Interventions
First Posted Date
2019-12-04
Last Posted Date
2019-12-04
Lead Sponsor
Far Eastern Memorial Hospital
Target Recruit Count
200
Registration Number
NCT04185129
Locations
🇨🇳

Far Eastern Memorial Hospital, Taipei, Taiwan

Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)

Phase 3
Completed
Conditions
Rhinitis, Allergic, Seasonal
Interventions
First Posted Date
2019-03-19
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
679
Registration Number
NCT03879772

A Study Comparing the Effects of Trimbow to Fostair in COPD

Phase 4
Completed
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Drug: Fostair pMDI
First Posted Date
2019-02-15
Last Posted Date
2020-01-27
Lead Sponsor
Medicines Evaluation Unit Ltd
Target Recruit Count
23
Registration Number
NCT03842904
Locations
🇬🇧

The Medicines Evaluation Unit (MEU), Manchester, United Kingdom

Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis

Phase 4
Completed
Conditions
Allergic Rhinitis
Interventions
First Posted Date
2016-01-06
Last Posted Date
2017-11-20
Lead Sponsor
Stefania La Grutta, MD
Target Recruit Count
68
Registration Number
NCT02646904
Locations
🇮🇹

Institute of Biomedicine and Molecular Immunology, IBIM, Palermo, Italy

🇮🇹

Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Sicily, Italy

© Copyright 2025. All Rights Reserved by MedPath